Your session is about to expire
← Back to Search
Direct Thrombin Inhibitor
Dabigatran Etexilate Mesylate for Acute Pancreatitis
Phase 1
Waitlist Available
Led By Yan Bi, MD, PhD
Research Sponsored by Mayo Clinic
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up one year
Awards & highlights
Study Summary
This study is evaluating whether a drug called dabigatran may help treat acute pancreatitis.
Eligible Conditions
- Acute Pancreatitis
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ one year
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~one year
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Adverse Events
Trial Design
2Treatment groups
Active Control
Group I: Dabigatran Etexilate MesylateActive Control2 Interventions
Dabigatran 150mg BID for 3 days
Group II: Standard of CareActive Control1 Intervention
Standard treatment for acute pancreatitis
Find a Location
Who is running the clinical trial?
Mayo ClinicLead Sponsor
3,212 Previous Clinical Trials
3,767,036 Total Patients Enrolled
2 Trials studying Acute Pancreatitis
111 Patients Enrolled for Acute Pancreatitis
Yan Bi, MD, PhDPrincipal Investigator - Mayo Clinic
Mayo Clinic Hospital Jacksonville
1 Previous Clinical Trials
324 Total Patients Enrolled
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Share this study with friends
Copy Link
Messenger